US 7,320,969 B2 | ||
Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | ||
Robert G. Bell, Palm Harbor, Fla. (US); Carole Ben-Maimon, Merion, Pa. (US); and Beata Iskold, Livingston, N.J. (US) | ||
Assigned to Duramed Pharmaceuticals, Inc., Cincinnati, Ohio (US) | ||
Filed on Dec. 04, 2002, as Appl. No. 10/309,313. | ||
Claims priority of provisional application 60/335807, filed on Dec. 05, 2001. | ||
Prior Publication US 2003/0139381 A1, Jul. 24, 2003 | ||
Int. Cl. A61K 31/56 (2006.01) |
U.S. Cl. 514—170 [514/171; 514/182] | 19 Claims |
1. A method of contraception in a female in need thereof, the method comprising administering to the female a dosage comprising
a combination of estrogen and progestin for a period of 81 to 89 consecutive days, followed by administration of a dosage
consisting essentially of estrogen for a period of 2 to 8 consecutive days,
wherein the estrogen that is administered in combination with progestin for the period of 81 to 89 consecutive days is administered
in a daily amount equivalent to about 10 μg to about 50 μg of ethinyl estradiol,
the estrogen that is administered for the period of 2 to 8 consecutive days is administered in a daily amount equivalent to
about 5 μg to about 10 μg of ethinyl estradiol, and
the progestin that is administered for the period of 81 to 89 consecutive days is administered in a daily amount of about
150 μg of levonorgestrel.
|